- Home
- TKNO vs IMMP Comparison
TKNO vs IMMP Comparison
Compare TKNO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- IMMP
- Stock Information
- Founded
- TKNO 1996
- IMMP 1987
- Country
- TKNO United States
- IMMP Australia
- Employees
- TKNO N/A
- IMMP N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- IMMP Health Care
- Exchange
- TKNO Nasdaq
- IMMP Nasdaq
- Market Cap
- TKNO 244.7M
- IMMP 264.7M
- IPO Year
- TKNO 2021
- IMMP N/A
- Fundamental
- Price
- TKNO $5.91
- IMMP $2.05
- Analyst Decision
- TKNO Buy
- IMMP Buy
- Analyst Count
- TKNO 2
- IMMP 2
- Target Price
- TKNO $5.00
- IMMP $8.50
- AVG Volume (30 Days)
- TKNO 269.2K
- IMMP 106.2K
- Earning Date
- TKNO 11-07-2024
- IMMP 11-26-2024
- Dividend Yield
- TKNO N/A
- IMMP N/A
- EPS Growth
- TKNO N/A
- IMMP N/A
- EPS
- TKNO N/A
- IMMP N/A
- Revenue
- TKNO $36,347,000.00
- IMMP $2,563,302.00
- Revenue This Year
- TKNO $3.56
- IMMP N/A
- Revenue Next Year
- TKNO $13.31
- IMMP $10.84
- P/E Ratio
- TKNO N/A
- IMMP N/A
- Revenue Growth
- TKNO N/A
- IMMP 9.59
- 52 Week Low
- TKNO $1.16
- IMMP $1.58
- 52 Week High
- TKNO $7.92
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- TKNO 44.25
- IMMP 55.82
- Support Level
- TKNO $6.15
- IMMP $1.85
- Resistance Level
- TKNO $7.92
- IMMP $2.06
- Average True Range (ATR)
- TKNO 0.69
- IMMP 0.10
- MACD
- TKNO -0.17
- IMMP 0.03
- Stochastic Oscillator
- TKNO 0.50
- IMMP 70.89
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.